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iDITORIAL COMMENT
latelets, the
ardiologist, and
oronary Artery Disease:
oving Beyond Aggregation*
eal S. Kleiman, MD, FACC
ouston, Texas
everal decades ago, the platelet was viewed as a passive
nucleate participant in thrombosis. Its role was thought to
e primarily mechanical: to form stable hemostatic plugs
hat could serve as physical barriers to the flow of blood into
nwanted places. For approximately a decade, the primary
ocus of cardiologists and other practitioners involved in the
anagement of atherosclerosis was directed toward inhibi-
ion of the platelet aggregation response. Initially described
y Born and Cross (1), this response could be measured
asily in either platelet-rich plasma or, with modifications,
n whole blood. The description of glycoprotein (GP)
Ib/IIIa, the cellular receptor necessary for aggregation (2)
nd the characterization of a population in whom its
See page 1982
bsence (or dysfunction) is reasonably well tolerated (3) led
o the development of antibodies, peptides, and wholly
ynthetic compounds designed specifically to inhibit platelet
ggregation. The successful use of these compounds in
atients undergoing percutaneous coronary interventions
nd in those hospitalized with acute coronary syndromes
ACS) (4) further directed the attention of the cardiology
ommunity to believe that antiplatelet therapy simply meant
revention of aggregation.
Three surprising findings in the clinical realm led to the
e-evaluation of these postulates. First was the finding in
ore than 19,000 patients enrolled in the Clopidogrel
ersus Aspirin in Patients at Risk of Ischaemic Events
CAPRIE) study that a daily dose of clopidogrel, a drug
hat led to relatively minor decrements in the aggregation
esponse compared with GP IIb/IIIa antagonists, led to a
oderate but significant reduction in atherosclerotic mor-
idity and mortality compared with aspirin (5). When
ombined with aspirin in patients presenting with ACS in
he Clopidogrel in Unstable Angina to Prevent Recurrent
vents (CURE) trial, clopidogrel reduced a composite of
ardiovascular death, myocardial infarction, and stroke by
0% compared with aspirin alone (6). A second surprise was
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiac Catheterization Laboratory, Baylor College of Medicine,vethodist DeBakey Heart Center, Houston, Texas.hat the combination of the thienopyridine ticlopidine with
spirin was more successful than either aspirin alone or
arfarin with aspirin at preventing subacute thrombosis of
ntracoronary stents (7). The final unexpected finding con-
isted of serial observations that oral antagonists of GP
Ib/IIIa consistently were associated with increases rather
han decreases in cardiovascular mortality despite potent
nd sustained inhibition of platelet aggregation (8). Initially
hought to be a consequence of poor pharmacokinetic
rofiles of the early oral agents, these findings were so
onsistent from trial to trial that they eventually led to
e-examination of the basic paradigm. In fact, these obser-
ations were accompanied by findings suggesting that the
ame agents that prevented platelets from aggregating could
imultaneously cause activation of the platelet (9) and
ncreased expression of CD-40 ligand (CD 154) (10), a
olecular messenger through which activated platelets ini-
iate an inflammatory response involving endothelial cells
nd leukocytes.
Taken in aggregate, these findings suggest that the
echanism through which thienopyridines benefit patients
ith atherosclerosis is likely to extend beyond their rela-
ively mild antiaggregation effects. Thienopyridines, or
ather their active metabolites, affect platelet function by
nhibiting the action of adenosine diphosphate (ADP) on
ne of the three platelet purinergic receptors, P2Y12 (11). In
oing so, they antagonize the direct effect of ADP released
y cells as they are lysed in a developing thrombus, as well
s prevent amplification of the initial platelet stimulus that
ccurs when activated platelets release ADP. Blockade of
2Y12 inhibits expression of the active form of GP IIb/IIIa,
hus limiting the formation of large stable platelet aggre-
ates, and prevents platelets from undergoing the shape
hange reaction, one consequence of which is the expression
f P-selectin on the platelet surface (12). In the current issue
f the Journal, Xiao and The´roux (13) have placed these
ctions into a clinical perspective and as a result have
dvanced the field by a giant step. In patients treated with
spirin and clopidogrel for an acute coronary syndrome, they
ound that a 300 mg loading dose of clopidogrel (in addition
o aspirin) produced a modest reduction in turbidimetric
latelet aggregation in response to two commonly studied
gonists. A more novel finding was an accompanying
eduction in platelet-leukocyte complexes and in circulating
evels of soluble P-selectin and soluble CD-40 ligand.
reatment with clopidogrel reduced circulating levels of
latelet-leukocyte complexes to levels observed in healthy
olunteers. In contradistinction, GP IIb/IIIa antagonists,
ore potent antagonists of platelet aggregation, have been
eported to increase, decrease, or not affect platelet-
eukocyte complex formation (14–17). Much to their credit,
iao and The´roux used two different techniques to demon-
trate that treatment with clopidogrel interferes with the
nteraction between platelets and leukocytes. In many pre-
ious studies, distinction between antiplatelet effects and
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Editorial Comment June 2, 2004:1989–91revention of platelet-leukocyte adhesion (i.e., complex
ormation) has been obscured by flow cytometric techniques
hat count platelet-leukocyte complexes by measuring the
uorescence of platelets bound to leukocytes. Because acti-
ated platelets bind to other platelets as well as to leuko-
ytes, merely counting platelet numbers within a leukocyte
ate cannot distinguish whether the number of platelets per
latelet-leukocyte complex is diminished or whether the
bsolute number of complexes is decreased. These authors
ave measured both entities and demonstrated that the
umbers of complexes as well as the platelet density per
omplex are decreased.
This finding is of importance because the details of
nteractions between platelets and leukocytes are only be-
inning to be appreciated. As leukocytes migrate to sites of
ascular injury, they are able to roll along the endothelial
urface without becoming activated. There, they are exposed
o a variety of activating factors, including activated endo-
helial cells and activated platelets adherent to the suben-
othelium. Both of the latter cell types express P-selectin on
heir surfaces. The presentation of activated platelets to the
eukocyte is believed to occur as a multi-step process
eginning with the attachment of platelet P-selectin to
eukocyte PSGL-1, a receptor constitutively expressed on
eukocytes. Blocking antibodies directed at either P-selectin
r PSGL-1 can prevent this interaction or even disaggregate
latelet-leukocyte complexes (14). Subsequent activation of
he leukocyte leads to the formation of much firmer bonds
hrough integrins, most likely CD 11b/CD18 and its
ounter-receptor GPIb. This process has two important
mplications for those interested in the mechanisms of
hrombosis and inflammation. First, because the expression
f P-selectin on the platelet surface requires that the platelet
tself be activated, platelet-leukocyte complexes have long
een regarded as markers of platelet activation. Second, it is
ow becoming clear that these interactions have functional
mplications. Activated platelets are known to stimulate
roinflammatory and prothrombotic responses in leukocytes
nd endothelial cells (18). Most of the steps involved have
een worked out in monocytes and monocyte-derived cell
ines. Ligation of PSGL-1 by P-selectin results in several
mportant changes in the monocyte, including conversion of
he cell membrane to a prothrombotic surface capable of
inding procoagulant proteins, surface expression of tissue
actor that can initiate the coagulation cascade, and permit-
ing the activated monocyte to diapedese across an endo-
helial surface into the subendothelium. It also appears that
rafficking in tissue factor occurs between platelets and
onocytes. Blockade of P2Y12 markedly reduces tissue
actor expression on monocytes in a whole blood model
19). The current findings thus reveal that in the patient
roup shown to benefit from treatment with clopidogrel,
lockade of platelet P2Y12 can prevent platelet contact with
onocytes and neutrophils. The next step in understanding
hese mechanisms will be to determine whether interdiction
f this pathway has functional consequences (i.e., whether itnhibits leukocyte migration into the diseased subintima and
hether it prevents leukocytes from exerting proinflamma-
ory and other prothrombotic effects). Such a finding would
rovide considerable support for the hypothesis that an
ndirect anti-inflammatory is part of the mechanism of the
ong-term benefit of thienopyridines observed after percu-
aneous interventions and in patients with ACS.
Several other questions also need to be answered. Recent
ata indicate that at any given time after administering
lopidogrel, the degree to which platelet aggregation and
xpression of P-selectin are inhibited is subject to wide
ariation. This phenomenon, termed “resistance,” may be
ue to variations in P2Y12 receptor expression, intracellular
ignaling mechanisms, or the production of the active
etabolite (20). Polymorphisms of P2Y12 receptor with
unctional consequences in vitro also have been reported
21). It is likely but not established that the anti-
nflammatory effect of clopidogrel also is subject to such
ariability. Questions also remain about the appropriate
oading dose of clopidogrel. In the initial studies, patients
ere begun on 75 mg during the first day of therapy.
ubsequent data indicated that a loading dose of 300 mg
ould achieve more rapid inhibition of platelet aggregation,
nd this dose was used in the CURE trial (22). More recent
ata indicate that a loading dose of 600 mg is able to inhibit
latelet aggregation even more rapidly (23); this dose has
een used in a more recent trial in patients undergoing
ercutaneous coronary intervention. Will the 600-mg dose
ave more potent or more reliable effects on platelet-
eukocyte complexes and their functional sequelae? Finally,
ill concomitant blockade of the other human platelet
urinergic receptor, P2Y1, enhance this effect? Although
hese questions are not correctly answered, it is important to
ecognize that an important step has been made here that
hould help guide future research directed at platelet puri-
ergic receptors and their antagonism.
eprint requests and correspondence: Dr. Neal. S. Kleiman, 6565
annin, MS F1090, Houston, Texas 77030. E-mail: nkleiman@
cm.tmc.edu.
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